Close menu




November 25th, 2021 | 12:44 CET

BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?

  • Biotechnology
Photo credits: pixabay.com

The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".

time to read: 2 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    Cardiol Therapeutics: Get in now after successful capital increase?

    In addition to vaccines, drugs are the great hope for getting the Corona pandemic under control. So far, there is no approved drug with proven efficacy. Cardiol Therapeutics (Cardiol) is researching such a drug for COVID-19 patients and has reached an important milestone. The US FDA approved the treatment of hospitalized COVID-19 patients with CardiolRX, Cardiol's main product, as part of a clinical study. The Canadian Company is also researching a compound related to acute myocarditis and regeneration of the heart muscle. Currently, this is in phase 2.

    It is well known that research costs money. Nevertheless, Cardiol's recent capital increase caught investors on the wrong foot. Although the issuance was placed within a few hours and the Company received about USD 50 million, the share price dropped significantly and is currently quoted at CAD 2.60. As a result, the share has lost around 50% of its value within 4 weeks. However, progress is being made in drug development. According to the experts at GBC Research, this is a good time to buy. Following the capital increase, the analyst house from Augsburg has again recommended the Cardiol share as a buy. The experts believe study results for the COVID-19 drug will be released in the fourth quarter of 2021 or the first quarter of 2022. GBC's price target for the Cardiol share is CAD 17.49, considerably higher than the current price.

    Valneva: Recovery after the Flash Crash?

    The Valneva share caused astonishment on Tuesday. Within less than half an hour, the share price plummeted from over EUR 21 to as low as EUR 17.66. But there was positive news. Valneva and the EU Commission signed the contract for the supply of Valneva's COVID-19 vaccine VLA2001. According to the agreement, the French Company is to supply 24.3 million doses of the vaccine in the second and third quarters of 2022. A total of up to 60 million doses are to be supplied in 2022 and 2023. The prerequisite is that the vaccine is approved. Study results published to date have been positive. Many hopes rest on VLA2001 to increase the vaccination rate in Germany and other countries. This is because it is an inactivated vaccine. The vaccine is based on the virus in its natural form, which is chemically inactivated and cannot reproduce in the vaccinated person's body. However, upon contact, the body reacts with the same immune response as the active coronavirus and forms antibodies.

    BioNTech: Boosters and compulsory vaccinations drive the share price up

    Things are currently going well at BioNTech. The share has left its correction behind and is once again setting its sights on the EUR 300 mark. Booster vaccinations are picking up speed. In Germany alone, Health Minister Jens Spahn had to order additional doses. Demand has risen insanely in the past two weeks, Spahn said, and they will deliver 6 million BioNTech doses starting this week alone. But there is more good news for BioNTech. Because soon, children as young as five could also be vaccinated in Europe. Today, the European Medicines Agency (EMA) is expected to decide whether to approve BioNTech's vaccine for children in this age group. So far, there is no Corona vaccine approved for children under the age of twelve in the EU. This mixed situation should give the BioNTech share further impetus.


    COVID-19 continues to keep the world busy. Vaccine manufacturers like BioNTech and Valneva are benefiting. Effective drugs will also become cash cows, and Cardiol is going full throttle to develop one.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on June 9th, 2023 | 07:30 CEST

    Defence Therapeutics, Bayer AG, Palantir Technologies - Networked data revolutionizes the future of production

    • Biotechnology
    • AI
    • Pharma
    • Energy

    In the battle against cancer, the Canadian biotech company Defence Therapeutics is focusing on pancreatic cancer cells. They are currently conducting a new study that aims to develop a vaccination against pancreatic cancer. A crucial factor driving this project is the utilization of networked data. Bayer AG is also active in Canada. The Company is partnering with Acuitas to develop new business areas in the field of mRNA-based gene therapy. Palantir Technologies' move to become active in the energy sector is also new. A battery plant in North America serves as a sandbox for this. We provide insight into the latest developments for investors with a growth strategy.

    Read

    Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST

    MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction

    • Biotechnology
    • Pharma
    • Cancer

    Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.

    Read

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.

    Read